In this sense, several studies support that the pharmacological treatment with the specific CB2 agonist JWH-133 ameliorates cognitive function and long-term recognition memory decline in AD-model animals, such as AβPP/PS1 mice [27,30,62], and APP 2576 mice [29] at 6 and 11 months of age, respectively. This evidence concerns the gene CNR2 and Alzheimer disease.